Date | Time | Source | Headline | Symbol | Company |
04/03/2024 | 9:00AM | GlobeNewswire Inc. | XOMA Corporation Announces Closing of Tender Offer | NASDAQ:KNTE | Kinnate Biopharma Inc |
03/19/2024 | 4:05PM | GlobeNewswire Inc. | XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. | NASDAQ:KNTE | Kinnate Biopharma Inc |
03/05/2024 | 5:00PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:KNTE | Kinnate Biopharma Inc |
03/05/2024 | 5:00PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:KNTE | Kinnate Biopharma Inc |
03/04/2024 | 5:27PM | Edgar (US Regulatory) | Form SC 14D9 - Solicitation, recommendation statements | NASDAQ:KNTE | Kinnate Biopharma Inc |
03/01/2024 | 8:53AM | Edgar (US Regulatory) | Form SC14D9C - Written communication relating to third party tender offer | NASDAQ:KNTE | Kinnate Biopharma Inc |
03/01/2024 | 8:50AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KNTE | Kinnate Biopharma Inc |
03/01/2024 | 8:35AM | PR Newswire (US) | Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories | NASDAQ:KNTE | Kinnate Biopharma Inc |
03/01/2024 | 8:35AM | PR Newswire (US) | Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories | NASDAQ:KNTE | Kinnate Biopharma Inc |
03/01/2024 | 8:35AM | PR Newswire (Canada) | Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories | NASDAQ:KNTE | Kinnate Biopharma Inc |
03/01/2024 | 8:30AM | GlobeNewswire Inc. | Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories | NASDAQ:KNTE | Kinnate Biopharma Inc |
02/21/2024 | 6:01AM | Edgar (US Regulatory) | Form SC14D9C - Written communication relating to third party tender offer | NASDAQ:KNTE | Kinnate Biopharma Inc |
02/16/2024 | 5:57PM | PR Newswire (US) | ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc. | NASDAQ:KNTE | Kinnate Biopharma Inc |
02/16/2024 | 10:46AM | PR Newswire (US) | Kuehn Law Encourages KNTE, FANG, HAYN, and VINE Investors to Contact Law Firm | NASDAQ:KNTE | Kinnate Biopharma Inc |
02/16/2024 | 9:10AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KNTE | Kinnate Biopharma Inc |
02/16/2024 | 8:00AM | GlobeNewswire Inc. | XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right | NASDAQ:KNTE | Kinnate Biopharma Inc |
02/16/2024 | 8:00AM | GlobeNewswire Inc. | Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share | NASDAQ:KNTE | Kinnate Biopharma Inc |
02/14/2024 | 9:21AM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:KNTE | Kinnate Biopharma Inc |
01/16/2024 | 4:05PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KNTE | Kinnate Biopharma Inc |
12/05/2023 | 5:00PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:KNTE | Kinnate Biopharma Inc |
12/05/2023 | 5:00PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:KNTE | Kinnate Biopharma Inc |
11/15/2023 | 9:00AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KNTE | Kinnate Biopharma Inc |
11/09/2023 | 4:21PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:KNTE | Kinnate Biopharma Inc |
11/09/2023 | 4:14PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KNTE | Kinnate Biopharma Inc |
11/09/2023 | 4:05PM | GlobeNewswire Inc. | Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates | NASDAQ:KNTE | Kinnate Biopharma Inc |
09/18/2023 | 4:28PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KNTE | Kinnate Biopharma Inc |
09/18/2023 | 4:10PM | GlobeNewswire Inc. | Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring | NASDAQ:KNTE | Kinnate Biopharma Inc |
09/06/2023 | 5:00PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:KNTE | Kinnate Biopharma Inc |
09/06/2023 | 5:00PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:KNTE | Kinnate Biopharma Inc |
08/08/2023 | 4:48PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:KNTE | Kinnate Biopharma Inc |